The potential of this approach to address some of the inherent and emerging limitations of the cGAS-STING axis in cancer immunotherapy is considered, where it becomes evident that low doses of the DNA-damaging agent will be required to avoid detrimental immunotoxicity, and will need to be supported with the use of targeted nanoparticle delivery systems. The gene discussed is CGAS; the disease is cancer.